Diagnosis and treatment of primary aldosteronism

Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet. Diabetes & endocrinology 2021-12, Vol.9 (12), p.876-892
Hauptverfasser: Reincke, Martin, Bancos, Irina, Mulatero, Paolo, Scholl, Ute I, Stowasser, Michael, Williams, Tracy Ann
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 892
container_issue 12
container_start_page 876
container_title The lancet. Diabetes & endocrinology
container_volume 9
creator Reincke, Martin
Bancos, Irina
Mulatero, Paolo
Scholl, Ute I
Stowasser, Michael
Williams, Tracy Ann
description Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.
doi_str_mv 10.1016/S2213-8587(21)00210-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_pubmed_primary_34798068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2213858721002102</els_id><sourcerecordid>2600286915</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</originalsourceid><addsrcrecordid>eNqFkE9PwzAMxSMEYtPYRwD1OA4FJ23S5ITQ-CtN4gCco7RxUVDbjKRD4tvTbWVXTras92y_HyHnFK4oUHH9yhjNUsllsWD0EoBRSNkRmY5jxY8PvSwmZB7jJwBQ4JmQcEomWV4oCUJOCdw589H56GJiOpv0AU3fYtcnvk7WwbUm_CSmsT72GHznYntGTmrTRJyPdUbeH-7flk_p6uXxeXm7SqtcZn1aMFDS1hKFVQplLfMyL5Bntam5ZCWvqTJY5oqCEFAgitIayoHlUEAuIM9mZLHfuw7-a4Ox162LFTaN6dBvomZiiC2FonyQ8r20Cj7GgLUeP9cU9JaX3vHSWxiaUb3jpdnguxhPbMoW7cH1R2cQ3OwFOAT9dhh0rBx2FVoXsOq19e6fE7_NRXhl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2600286915</pqid></control><display><type>article</type><title>Diagnosis and treatment of primary aldosteronism</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Reincke, Martin ; Bancos, Irina ; Mulatero, Paolo ; Scholl, Ute I ; Stowasser, Michael ; Williams, Tracy Ann</creator><creatorcontrib>Reincke, Martin ; Bancos, Irina ; Mulatero, Paolo ; Scholl, Ute I ; Stowasser, Michael ; Williams, Tracy Ann</creatorcontrib><description>Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.</description><identifier>ISSN: 2213-8587</identifier><identifier>EISSN: 2213-8595</identifier><identifier>DOI: 10.1016/S2213-8587(21)00210-2</identifier><identifier>PMID: 34798068</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adenoma - complications ; Adrenalectomy ; Adrenocortical Adenoma - complications ; Aldosterone ; Humans ; Hyperaldosteronism - diagnosis ; Hyperaldosteronism - genetics ; Hyperaldosteronism - therapy ; Hypertension - complications ; Quality of Life</subject><ispartof>The lancet. Diabetes &amp; endocrinology, 2021-12, Vol.9 (12), p.876-892</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</citedby><cites>FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34798068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reincke, Martin</creatorcontrib><creatorcontrib>Bancos, Irina</creatorcontrib><creatorcontrib>Mulatero, Paolo</creatorcontrib><creatorcontrib>Scholl, Ute I</creatorcontrib><creatorcontrib>Stowasser, Michael</creatorcontrib><creatorcontrib>Williams, Tracy Ann</creatorcontrib><title>Diagnosis and treatment of primary aldosteronism</title><title>The lancet. Diabetes &amp; endocrinology</title><addtitle>Lancet Diabetes Endocrinol</addtitle><description>Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.</description><subject>Adenoma - complications</subject><subject>Adrenalectomy</subject><subject>Adrenocortical Adenoma - complications</subject><subject>Aldosterone</subject><subject>Humans</subject><subject>Hyperaldosteronism - diagnosis</subject><subject>Hyperaldosteronism - genetics</subject><subject>Hyperaldosteronism - therapy</subject><subject>Hypertension - complications</subject><subject>Quality of Life</subject><issn>2213-8587</issn><issn>2213-8595</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwzAMxSMEYtPYRwD1OA4FJ23S5ITQ-CtN4gCco7RxUVDbjKRD4tvTbWVXTras92y_HyHnFK4oUHH9yhjNUsllsWD0EoBRSNkRmY5jxY8PvSwmZB7jJwBQ4JmQcEomWV4oCUJOCdw589H56GJiOpv0AU3fYtcnvk7WwbUm_CSmsT72GHznYntGTmrTRJyPdUbeH-7flk_p6uXxeXm7SqtcZn1aMFDS1hKFVQplLfMyL5Bntam5ZCWvqTJY5oqCEFAgitIayoHlUEAuIM9mZLHfuw7-a4Ox162LFTaN6dBvomZiiC2FonyQ8r20Cj7GgLUeP9cU9JaX3vHSWxiaUb3jpdnguxhPbMoW7cH1R2cQ3OwFOAT9dhh0rBx2FVoXsOq19e6fE7_NRXhl</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Reincke, Martin</creator><creator>Bancos, Irina</creator><creator>Mulatero, Paolo</creator><creator>Scholl, Ute I</creator><creator>Stowasser, Michael</creator><creator>Williams, Tracy Ann</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Diagnosis and treatment of primary aldosteronism</title><author>Reincke, Martin ; Bancos, Irina ; Mulatero, Paolo ; Scholl, Ute I ; Stowasser, Michael ; Williams, Tracy Ann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-72098df8e6d99e8f84b47e53faf582b5f19aeb49106607ee6bda1502407046043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoma - complications</topic><topic>Adrenalectomy</topic><topic>Adrenocortical Adenoma - complications</topic><topic>Aldosterone</topic><topic>Humans</topic><topic>Hyperaldosteronism - diagnosis</topic><topic>Hyperaldosteronism - genetics</topic><topic>Hyperaldosteronism - therapy</topic><topic>Hypertension - complications</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reincke, Martin</creatorcontrib><creatorcontrib>Bancos, Irina</creatorcontrib><creatorcontrib>Mulatero, Paolo</creatorcontrib><creatorcontrib>Scholl, Ute I</creatorcontrib><creatorcontrib>Stowasser, Michael</creatorcontrib><creatorcontrib>Williams, Tracy Ann</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet. Diabetes &amp; endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reincke, Martin</au><au>Bancos, Irina</au><au>Mulatero, Paolo</au><au>Scholl, Ute I</au><au>Stowasser, Michael</au><au>Williams, Tracy Ann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis and treatment of primary aldosteronism</atitle><jtitle>The lancet. Diabetes &amp; endocrinology</jtitle><addtitle>Lancet Diabetes Endocrinol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>9</volume><issue>12</issue><spage>876</spage><epage>892</epage><pages>876-892</pages><issn>2213-8587</issn><eissn>2213-8595</eissn><abstract>Primary aldosteronism is a common cause of secondary hypertension associated with excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it does not have a specific, easily identifiable feature and clinicians can be poorly aware of the disease. The diagnostic investigation is a multistep process of screening, confirmatory testing, and subtype differentiation of unilateral from bilateral forms for therapeutic management. Adrenal venous sampling is key for reliable subtype identification, but can be bypassed in patients with specific characteristics. For unilateral disease, surgery offers the possibility of cure, with total laparoscopic unilateral adrenalectomy being the treatment of choice. Bilateral forms are treated mainly with mineralocorticoid receptor antagonists. The goals of treatment are to normalise both blood pressure and excessive aldosterone production, and the primary aims are to reduce associated comorbidities, improve quality of life, and reduce mortality. Prompt diagnosis of primary aldosteronism and the use of targeted treatment strategies mitigate aldosterone-specific target organ damage and with appropriate patient management outcomes can be excellent. Advances in molecular histopathology challenge the traditional concept of primary aldosteronism as a binary disease, caused by either a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia. Somatic mutations drive autonomous aldosterone production in most adenomas. Many of these same mutations have been identified in nodular lesions adjacent to an aldosterone-producing adenoma and in patients with bilateral disease. In addition, germline mutations cause rare familial forms of aldosteronism (familial hyperaldosteronism types 1–4). Genetic testing for inherited forms in suspected cases of familial hyperaldosteronism avoids the burdensome diagnostic investigation in positive patients. In this Review, we discuss advances and future management approaches in the diagnosis of primary aldosteronism.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34798068</pmid><doi>10.1016/S2213-8587(21)00210-2</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2213-8587
ispartof The lancet. Diabetes & endocrinology, 2021-12, Vol.9 (12), p.876-892
issn 2213-8587
2213-8595
language eng
recordid cdi_pubmed_primary_34798068
source MEDLINE; Alma/SFX Local Collection
subjects Adenoma - complications
Adrenalectomy
Adrenocortical Adenoma - complications
Aldosterone
Humans
Hyperaldosteronism - diagnosis
Hyperaldosteronism - genetics
Hyperaldosteronism - therapy
Hypertension - complications
Quality of Life
title Diagnosis and treatment of primary aldosteronism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A49%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20and%20treatment%20of%20primary%20aldosteronism&rft.jtitle=The%20lancet.%20Diabetes%20&%20endocrinology&rft.au=Reincke,%20Martin&rft.date=2021-12&rft.volume=9&rft.issue=12&rft.spage=876&rft.epage=892&rft.pages=876-892&rft.issn=2213-8587&rft.eissn=2213-8595&rft_id=info:doi/10.1016/S2213-8587(21)00210-2&rft_dat=%3Cproquest_cross%3E2600286915%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2600286915&rft_id=info:pmid/34798068&rft_els_id=S2213858721002102&rfr_iscdi=true